Table 4.

Cases of tuberculosis (TB) and relative incidence rate (IR) in patients receiving IL-12, IL-23, IL-17 inhibitors.

IL-12, IL-23, IL-17 Inhibitors
Drug	Disease	Study type	No~	Pt-yrs	Active TB cases	IR§	Rate general population*	Reference
Ustekinumab	PsA, PsO, CD	RCT	5884	4521	1	22.12	International	Ghosh et al.76
Ustekinumab	PsA	RCT	705	NA	0	NA	International	Ritchlin et al.72
Ustekinumab	PsA	LTE	615	NA	0	NA	International	Kavanaugh et al.73
Ustekinumab	PsA	RLS	65	NA	0	NA	7.0 (Italy)	Chimenti et al.74
Ustekinumab	CD	RCT	1177	NA	1	NA	International	Feagan et al.75
Ustekinumab	PsO	LTE	3117	8998	0	0.0	International	Lopez-Ferrer et al.77
Guselkumab	PsA	Phase II	100	NA	0	NA	International	Deodhar et al.85
Guselkumab	RA	Phase II	110	NA	0	NA	International	Smolen et al.86
Guselkumab	PsO	RCT	1283	NA	0	NA	International	Crowley et al.87
Rizankizumab	PsA	RCT	185	NA	0	NA	International	Mease et al.88
Rizankizumab	PsO	RCT	588	NA	0	NA	International	Crowley et al.87
Rizankizumab	PsO	RCT	301	NA	0	NA	International	Reich et al.89
Secukinumab	AS, PsA, PsO	RCT	7355	16,227	0	NA	International	Deodhar et al.95
Secukinumab	AS, PsA, PsO	LTE	NA	96,054	1	5.0	International	Deodhar et al.95
Secukinumab	PsO	RCT	3430	2725	0	0.0	International	van de Kerkhof et al.96
Secukinumab	PsO	RLS	96	104.5	0	0.0	43.0 (Taiwan)	Wu et al.83
Ixekizumab	AS	RCT	164	NA	0	NA	International	van der Heijde et al.97
Ixekizumab	PsA	RCT	1118	1373	0	0.0	International	Mease et al.98
Ixekizumab	PsO	RCT	5370	13,479	0	0	International	Romiti et al.99
Brodalumab	AS	RCT	80	NA	0	NA	International	Wei et al.100
Brodalumab	PsA	RCT	168	NA	0	NA	International	Mease et al.101

^~Number of patients included in the study.

^§per 100,000 patient-years.

^*IR for TB infection in general population of certain country per 100,000 population.

AS, ankylosing spondylitis; CD, Crohn’s disease; LTE, long-term extension; NA, not applicable; PsA, psoriatic arthritis; PsO, psoriasis; Pt-yrs, patient-years; RCT, randomized control trial; RLS, real-life study.